Physician profile
Jane Derrig
NPI 1265495758
$22,891.90
in general payments reported to CMS, 2019-2025
41 companies · $3,059 in 2025
The $3,059 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,431 · 2020: $3,197 · 2021: $3,593 · 2022: $3,835 · 2023: $3,333 · 2024: $2,444 · 2025: $3,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,836.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,722.47 | 2019-2025 | Enbrel, Otezla, Otezla |
| Pfizer INC. | $2,324.04 | 2019-2025 | |
| Abbvie INC. | $2,058.00 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $2,011.29 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $1,310.05 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $1,153.69 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Radius Health, INC. | $1,152.28 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $1,042.38 | 2019-2025 | |
| Lilly USA, LLC | $864.07 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $766.23 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $710.55 | 2019-2025 | Benlysta |
| Ferring Pharmaceuticals INC. | $547.55 | 2019-2025 | Euflexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.84 | 2020-2025 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $312.03 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $255.77 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Derrig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.